Freedom Biosciences, a US biotechnology platform developing next-generation psychedelic therapeutics, received an investment from LongeVC.
The amount of the deal was not disclosed.
The company intends to use the funds to expand operations and its development efforts.
Founded by Yale University professor Dr. John Krystal and PsyMed Ventures co-founder Dina Burkitbayeva, Freedom Biosciences is a clinical-stage biotechnology platform developing next-generation psychedelic therapeutics pioneering the use of ketamine and other compounds. Through its discovery platform, the company has identified the combinations of chemicals to advance the safety and therapeutic profiles of existing psychedelic therapeutics. With programs with clinical data and multiple exploratory programs, Freedom Biosciences has a diverse portfolio of assets positioned to change the way we currently treat mental health indications.
The company is supported by other psychedelics, biotech and longevity-focused funds and investors, including Marat Kichikov.
FinSMEs
15/02/2023